Nations Financial Group Inc. IA ADV lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 10.3% in ...
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 18, 2025 / Rancho BioSciences, the premier tech-enabled data science ...
2d
GlobalData on MSNBristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trialUS-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...
Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...
Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where ...
The company also issued a 2025 guidance that fell short of expectations, as some of the company’s older drugs face ...
Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...
This was the stock's third consecutive day of losses.
Shares in Bristol-Myers Squibb traded about 2.7% lower Thursday after the drug maker gave 2025 guidance that undershot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results